AVEO Pharmaceuticals Inc. (AVEO)

0.62
NASDAQ : Health Technology
Prev Close 0.62
Day Low/High 0.61 / 0.63
52 Wk Low/High 0.49 / 3.59
Avg Volume 3.58M
Exchange NASDAQ
Shares Outstanding 139.00M
Market Cap 84.82M
P/E Ratio N/A
Div & Yield N.A. (N.A)
AVEO Enters Into Research And Exclusive Option Agreement With Ophthotech For Tivozanib (VEGF Inhibitor) For The Treatment Of Ocular Diseases

AVEO Enters Into Research And Exclusive Option Agreement With Ophthotech For Tivozanib (VEGF Inhibitor) For The Treatment Of Ocular Diseases

AVEO Oncology (NASDAQ:AVEO) today announced that it has entered into a research and exclusive option agreement with Ophthotech Corporation, under which it has provided Ophthotech an exclusive license to investigate the...

AVEO Oncology Reports Third Quarter 2014 Financial Results

AVEO Oncology Reports Third Quarter 2014 Financial Results

AVEO Oncology (NASDAQ:AVEO) today reported its third quarter 2014 financial results and provided an overview of its progress toward achieving its strategic plan.

Leon Cooperman to Cash in on Atlas Energy Acquisition

Leon Cooperman to Cash in on Atlas Energy Acquisition

Doral Financial Corp. (NYSE:DRL), Nanosphere, Inc. (NASDAQ:NSPH) and Atlas Energy LP (NYSE:ATLS) made major gains early in the day this Monday. In the red are DryShips Inc. (NASDAQ:DRYS), Mitek Syst...

AVEO Oncology Announces Results From Phase 2 Clinical Studies Of Tivozanib In Patients With Advanced Colorectal And Kidney Cancers Presented At ESMO 2014 Congress

AVEO Oncology Announces Results From Phase 2 Clinical Studies Of Tivozanib In Patients With Advanced Colorectal And Kidney Cancers Presented At ESMO 2014 Congress

AVEO Oncology (NASDAQ:AVEO) today announced poster presentations for two Phase 2 clinical studies of tivozanib, one in metastatic colorectal cancer (mCRC) and one in renal cell carcinoma (RCC), at the 2014 Congress of...

AVEO And Biodesix Announce Exploratory Analysis Of VeriStrat-Selected Patients With Non-Small Cell Lung Cancer In Phase 2 Study Of Ficlatuzumab Presented At ESMO 2014 Congress

AVEO And Biodesix Announce Exploratory Analysis Of VeriStrat-Selected Patients With Non-Small Cell Lung Cancer In Phase 2 Study Of Ficlatuzumab Presented At ESMO 2014 Congress

AVEO Oncology (NASDAQ:AVEO) and Biodesix, Inc. today announced the presentation of results from a retrospective exploratory analysis using VeriStrat®, a commercially available serum protein test, to identify ...

AVEO Oncology Announces Presentation Of AV-380 Preclinical Data At 2nd Cancer Cachexia Conference

AVEO Oncology Announces Presentation Of AV-380 Preclinical Data At 2nd Cancer Cachexia Conference

AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from four preclinical studies of AV-380, the Company’s potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), ...

AVEO Oncology Announces Lease Termination And Amendment To Debt Financing Facility

AVEO Oncology Announces Lease Termination And Amendment To Debt Financing Facility

AVEO Oncology (NASDAQ:AVEO) today announced that, as part of its plan to decrease operational expenses, the Company has entered into a termination of its lease agreement pertaining to the Company’s headquarters...

Clinical Data On AVEO Oncology’s Ficlatuzumab And Tivozanib To Be Presented At The ESMO 2014 Congress

Clinical Data On AVEO Oncology’s Ficlatuzumab And Tivozanib To Be Presented At The ESMO 2014 Congress

AVEO Oncology (NASDAQ:AVEO) today announced that clinical data on ficlatuzumab, the Company’s hepatocyte growth factor (HGF) inhibitory antibody, as well as tivozanib, the Company’s inhibitor of vascular ...

First Week of AVEO April 2015 Options Trading

First Week of AVEO April 2015 Options Trading

Investors in AVEO Pharmaceuticals, Inc. saw new options begin trading this week, for the April 2015 expiration.

AVEO Oncology Reports Second Quarter 2014 Financial Results And Updates Progress On Strategic Plan

AVEO Oncology Reports Second Quarter 2014 Financial Results And Updates Progress On Strategic Plan

AVEO Oncology (NASDAQ:AVEO) today reported its second quarter 2014 financial results and provided an update on its progress toward achieving its strategic plan.

Another Gem for the Biotech Basket

Amid the basket's impressive performance, I'm adding Minerva.

Building a Biotech Basket

Borrowing a page from a master investor's playbook.

On being a Volvo investor in a Maserati market

On being a Volvo investor in a Maserati market

My philosophy is simple: buy low and sell high.

AVEO Oncology Announces Presentation Of AV-203 Phase 1 Results At 2014 American Society Of Clinical Oncology Annual Meeting

AVEO Oncology Announces Presentation Of AV-203 Phase 1 Results At 2014 American Society Of Clinical Oncology Annual Meeting

AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from a first-in-human Phase 1 study of AV-203, AVEO’s ErbB3 (HER3) inhibitory antibody candidate.

AVEO Oncology To Present At The Jefferies Global Healthcare Conference

AVEO Oncology To Present At The Jefferies Global Healthcare Conference

AVEO Oncology (NASDAQ:AVEO) today announced that Tuan Ha-Ngoc, chief executive officer, is scheduled to present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2014 at 8:30AM (ET) in New York City.

AVEO Oncology Reports First Quarter 2014 Financial Results

AVEO Oncology Reports First Quarter 2014 Financial Results

AVEO Oncology (NASDAQ:AVEO) today reported its first quarter 2014 financial results and provided an update on its progress toward achieving its strategic plan.

AVEO Oncology To Report First Quarter 2014 Financial Results On May 7, 2014

AVEO Oncology To Report First Quarter 2014 Financial Results On May 7, 2014

AVEO Oncology (NASDAQ: AVEO) today announced that the company will release its financial results for the first quarter ended March 31, 2014 after market close on Wednesday, May 7, 2014.

AVEO And Biodesix Partner To Co-Develop And Commercialize Ficlatuzumab With A Companion Diagnostic For Treatment Of NSCLC

AVEO And Biodesix Partner To Co-Develop And Commercialize Ficlatuzumab With A Companion Diagnostic For Treatment Of NSCLC

AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced that they have entered into a worldwide agreement to develop and commercialize AVEO’s hepatocyte growth factor (HGF) inhibitory antibody ...

AVEO Regains Worldwide Rights To AV-203

AVEO Regains Worldwide Rights To AV-203

AVEO Oncology (NASDAQ: AVEO) today announced that it has regained worldwide rights to AV-203, a clinical-stage ErbB3 (HER3) inhibitory antibody candidate, from Biogen Idec.

AVEO Oncology Reports Full Year 2013 Financial Results And Outlines 2014 Strategic Plan

AVEO Oncology Reports Full Year 2013 Financial Results And Outlines 2014 Strategic Plan

AVEO Oncology (NASDAQ: AVEO) today reported consolidated 2013 financial results and outlined its 2014 strategic plan and financial guidance.

AVEO Announces Timing For Conference Call To Discuss Year-End 2013 Financial Results And Provide Strategic Update For 2014

AVEO Announces Timing For Conference Call To Discuss Year-End 2013 Financial Results And Provide Strategic Update For 2014

AVEO Oncology (NASDAQ: AVEO) today announced that financial results for the company’s fourth quarter and year ended December 31, 2013 will be released after the market closes on Thursday, March 13, 2014.

AVEO And Astellas To End Worldwide Collaboration & License Agreement For Development And Commercialization Of Tivozanib

AVEO And Astellas To End Worldwide Collaboration & License Agreement For Development And Commercialization Of Tivozanib

AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced the companies will end their worldwide collaboration and license agreement for the development and commercialization of investigational...

AVEO And Astellas Discontinue Phase 2 Trial Of Tivozanib In Breast Cancer

AVEO And Astellas Discontinue Phase 2 Trial Of Tivozanib In Breast Cancer

AVEO Oncology (NASDAQ: AVEO) today announced that AVEO and Astellas Pharma Inc.

Six charts that show why this market is overvalued

Six charts that show why this market is overvalued

By any number of measures this market is getting pricey.

Biotech 2013 by the Numbers: A Blockbuster Year

Biotech 2013 by the Numbers: A Blockbuster Year

The biotech sector closed 2013 up 65%, greatly outperforming the broader markets.

The Worst Biotech CEO of 2013 Is...

The Worst Biotech CEO of 2013 Is...

Vical's Vijay Samant is this year's CEO loser by a wide margin.

AVEO Provides Update On Interim Analysis From Tivozanib Trial In Colorectal Cancer

AVEO Provides Update On Interim Analysis From Tivozanib Trial In Colorectal Cancer

AVEO Oncology (NASDAQ: AVEO) today announced that data from a planned interim analysis of the Phase 2 BATON ( Biomarker  Assessment of  Tivozanib in  ONcology) study in patients with colorectal cancer...

Your Vote Counts: Who Is the Worst Biotech CEO of 2013?

Your Vote Counts: Who Is the Worst Biotech CEO of 2013?

Amarin, Ariad, Vical, Dendreon and Aveo. You get to decide which CEO deserves to wear the badge of shame.

AVEO Reports Third Quarter 2013 Financial Results

AVEO Reports Third Quarter 2013 Financial Results

AVEO Oncology (NASDAQ: AVEO) today reported its third quarter 2013 financial results.

5 Biotech Stocks Under $10 for Your Watch List

5 Biotech Stocks Under $10 for Your Watch List

Keep an eye on these under-$10 biotech stocks.

TheStreet Quant Rating: D- (Sell)